TherapeuticsMD Inc (NASDAQ:TXMD) shares gapped down prior to trading on Thursday following insider selling activity. The stock had previously closed at $4.96, but opened at $4.85. TherapeuticsMD shares last traded at $4.63, with a volume of 4090637 shares traded.

Specifically, CEO Robert G. Finizio sold 184,000 shares of TherapeuticsMD stock in a transaction on Friday, September 21st. The stock was sold at an average price of $6.63, for a total value of $1,219,920.00. Following the completion of the sale, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at $122,559,256.17. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John C.K. Iv Milligan sold 258,000 shares of TherapeuticsMD stock in a transaction on Thursday, December 6th. The shares were sold at an average price of $4.77, for a total value of $1,230,660.00. Following the completion of the sale, the insider now directly owns 1,601,419 shares of the company’s stock, valued at approximately $7,638,768.63. The disclosure for this sale can be found here. Insiders have sold 3,925,728 shares of company stock valued at $21,315,073 in the last three months. 22.85% of the stock is currently owned by company insiders.

A number of equities research analysts have recently commented on the company. BidaskClub raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, November 23rd. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Friday, November 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TherapeuticsMD in a research report on Friday, November 23rd. Oppenheimer set a $14.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, November 7th. Finally, ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Monday, October 29th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. TherapeuticsMD currently has an average rating of “Buy” and a consensus target price of $13.45.

The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -12.76 and a beta of 1.35. The company has a debt-to-equity ratio of 0.55, a current ratio of 7.23 and a quick ratio of 7.15.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Wednesday, November 7th. The company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.06. TherapeuticsMD had a negative return on equity of 102.15% and a negative net margin of 757.59%. The firm had revenue of $3.47 million for the quarter, compared to analysts’ expectations of $4.43 million. During the same quarter last year, the firm earned ($0.07) earnings per share. The firm’s revenue for the quarter was down 21.5% compared to the same quarter last year. As a group, research analysts expect that TherapeuticsMD Inc will post -0.58 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. OppenheimerFunds Inc. boosted its holdings in TherapeuticsMD by 17.4% in the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after acquiring an additional 286,123 shares during the last quarter. BlackRock Inc. boosted its holdings in TherapeuticsMD by 4.4% in the second quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after acquiring an additional 608,470 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its holdings in TherapeuticsMD by 2,545.7% in the second quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock valued at $6,686,000 after acquiring an additional 1,031,000 shares during the last quarter. Twin Focus Capital Partners LLC acquired a new position in TherapeuticsMD in the second quarter valued at $187,000. Finally, Swiss National Bank boosted its holdings in TherapeuticsMD by 6.3% in the second quarter. Swiss National Bank now owns 320,300 shares of the company’s stock valued at $1,997,000 after acquiring an additional 18,900 shares during the last quarter. Hedge funds and other institutional investors own 72.66% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/therapeuticsmd-txmd-shares-gap-down-on-insider-selling/2667460.html.

TherapeuticsMD Company Profile (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.